Rockwell Medical, Inc. to Report First Quarter 2022 Financial and Operating Results on May 16, 2022
To access the conference call, please dial (877) 383-7438 (local) or (678) 894-3975 (international) at least 10 minutes prior to the start time and refer to conference ID 2599375. A live webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, https://ir.rockwellmed.com/. An archived webcast will be available on the Company's website approximately two hours after the event and will be available for 30 days.
To submit questions in advance, please email your questions to firstname.lastname@example.org.
Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients' lives. The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform. Rockwell Medical is also advancing its FPC platform by developing FPC for the treatment of iron deficiency anemia in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting. In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States. For more information, visit www.RockwellMed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/rockwell-medical-inc-to-report-first-quarter-2022-financial-and-operating-results-on-may-16-2022-301544919.html
Investors, Argot Partners, 212.600.1902, Rockwell@argotpartners.com; or Media, David Rosen, Argot Partners, 212.600.1902, email@example.com